Med Alliance Swiss Medical Technology

Medical Devices, Irvine Us, Nyon, California, 92602, United States, 51-200 Employees

Phone Number: 19*********

Who is MEDALLIANCE SWISS MEDICAL TECHNOLOGY

Founded in 2008, MedAlliance is a privately-owned medical technology company. It is headquartered in Nyon, Switzerland, with offices in Germany, Singapore, UK, and USA. MedAlliance specia...

Get Full Access

Headquarters: Irvine California Us, Nyon, California, 92602, United States
Date Founded: 2008
Employees: 51-200
Revenue: $5 Million to $10 Million
Active Tech Stack: See technologies

Industry: Medical Devices

SIC Code: 8742 | NAICS Code: 443142 | Show More

Does something look wrong? Fix it. | View contact records from MEDALLIANCE SWISS MEDICAL TECHNOLOGY

MedAlliance Swiss Medical Technology Org Chart and Mapping

Employees

David Nguyen

Associate Director - Clinical Affairs

Email
Phone

Saba Fatima

Clinical Research Analyst

Email
Phone

See Full Org Chart

View Email Formats for MedAlliance Swiss Medical Technology

You are signed out

Join Now

Free credits every month

Frequently Asked Questions Regarding MedAlliance Swiss Medical Technology

Answer: MedAlliance Swiss Medical Technology's headquarters are located at Irvine Us, Nyon, California, 92602, United States

Answer: Founded in 2008, MedAlliance is a privately-owned medical technology company. It is headquartered in Nyon, Switzerland, with offices in Germany, Singapore, UK, and USA. MedAlliance specializes in the development of ground-breaking technology and commercialisation of advanced drug device combination products for the treatment of coronary and peripheral artery disease. From the outset, MedAlliance has been dedicated to developing innovative drug-eluting balloons (DEBs) for patients suffering from life-threating diseases. Using breakthrough proprietary technology, MedAlliance has found a solution to the challenge of controlled and sustained sirolimus release with SELUTION SLRTM, a drug-eluting balloon catheter with sustained limus release technology, for the treatment of both coronary and peripheral artery disease. SELUTION SLRs technology involves unique MicroReservoirs made from biodegradable polymer intermixed with the anti-restenotic drug sirolimus. These MicroReservoirs provide controlled and sustained release of the drug. Extended release of sirolimus from stents has been proven highly efficacious in both coronary and peripheral vasculatures. MedAlliances proprietary CATTM (Cell Adherent Technology) enables the MicroReservoirs to be coated onto balloons and adhered to the vessel lumen when delivered via an angioplasty balloon. In February 2019, MedAlliance became the first DEB company in the world to receive Breakthrough Device Designation Status for a coronary DEB from the US Food and Drug Administration (FDA). SELUTION SLR has now achieved this status for a range of indications: the treatment of AV-Fistula; coronary in-stent restenosis and peripheral below-the-knee lesions. In February 2020 MedAlliance announced the award of its first CE Mark Approval: for SELUTION SLR in the treatment of peripheral arterial disease. In May 2020 the company announced the award of its second CE Mark: SELUTION SLR 014 PTCA for the treatment of coronary arterial disease.